Challenges in Preserving Access to Orphan Drugs Under an HTA Framework

Click for more information

Key Contacts

Jason Shafrin, Ph.D.

Senior Managing Director

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies Read More. However you may visit Cookie Settings to provide a controlled consent.

Cookie Settings Accept

Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT

Challenges in Preserving Access to Orphan Drugs Under an HTA Framework

<img width="15" height="15" src="https://www.ftichep.com/wp-content/themes/astra-child/assets/images/icon-contact.svg"> Key Contacts

Jason Shafrin, Ph.D.

Key Contacts